Applied Therapeutics, Inc. Forecast, price target & analysts
Applied Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Applied Therapeutics, Inc. Classifications & Recommendation:
Applied Therapeutics, Inc. Price Target
| Target Price | $2.55 |
| Price | $0.92 |
| Potential |
177.14%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Applied Therapeutics, Inc. 2026 .
The average Applied Therapeutics, Inc. target price is $2.55.
This is
177.14%
register free of charge
$5.25
470.59%
register free of charge
$1.52
64.66%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Applied Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Applied Therapeutics, Inc. stock has an average upside potential 2026 of
177.14%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.46 | 0.34 |
| 95.40% | 26.09% | |
| EBITDA Margin | -22,580.43% | -28,317.28% |
| 3,414.78% | 25.41% | |
| Net Margin | -22,960.87% | -24,378.44% |
| 1,815.32% | 6.17% |
6 Analysts have issued a sales forecast Applied Therapeutics, Inc. 2025 . The average Applied Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Applied Therapeutics, Inc. EBITDA forecast 2025. The average Applied Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Applied Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Applied Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.76 | -0.58 |
| 46.48% | 23.68% | |
| P/E | negative | |
| EV/Sales | 300.27 |
7 Analysts have issued a Applied Therapeutics, Inc. forecast for earnings per share. The average Applied Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Applied Therapeutics, Inc....
Current Applied Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | May 14 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| UBS |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| Baird |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Dec 23 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
UBS:
Locked
➜
Locked
|
Dec 02 2024 |
|
Locked
Baird:
Locked
➜
Locked
|
Nov 29 2024 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 29 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 29 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
